Scholarlink

Purpose of the Review <p>Our paper will outline a concise and comprehensive review of a practical approach to clinical metabolic dysfunction-associated steatotic liver disease (MASLD), incorporating considerations for risk factors, screening, diagnosis, and management, tailored for the pediatric demographic, with emphasis on risk factors and obesity medications.</p> Recent Findings <p>With the shift in terminology from non-alcoholic fatty liver disease (NAFLD) to MASLD, there is a clear need for pediatric guidelines that provide a practical approach to MASLD (Hampl et al. Pediatrics 151(1):e2022060640 [<CitationRef CitationID="CR1">1</CitationRef>]; Rinella et al. Hepatology 78(6):1966-1986 [<CitationRef CitationID="CR2">2</CitationRef>]; O'Hara et al. Obes Pillars 27(6):100066 [<CitationRef CitationID="CR3">3</CitationRef>]; Abou Jaoudeh et al. J Pediatr Gastroenterol Nutr 80(1):14-24 [<CitationRef CitationID="CR4">4</CitationRef>]). The combined MASLD guidelines from the European Association for the Study of Liver, Diabetes, and Obesity (EASL-EASD-EASO), published in July 2024 (EASL et al. J Hepatol 81(3):492-542 [<CitationRef CitationID="CR5">5</CitationRef>]), focused solely on the adult population. The most recent American Association for the Study of Liver Diseases AASLD publication in April 2025 offers an extensive evidence-based pediatric-focused practice statement on the evaluation and management of MASLD in children (Xanthakos et al. Hepatology [<CitationRef CitationID="CR6">6</CitationRef>]).</p> Summary <p>We hereby provide a concise and comprehensive review of a practical approach to clinical pediatric MASLD, with focus on risk factors, screening, management, and monitoring that could serve as a guide to primary care providers, gastroenterologists, hepatologists and other advanced health practitioners.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pediatric MASLD: The New Era Practical Approach to Assessment and Treatment of Pediatric MASLD with Emphasis on Risk Factors and Obesity Medications

  • 期刊论文

  • 发表日期：

    2025年12月29日

查看全文
  • Dieudonne Nonga,
  • Eileen Chaves,
  • Sindhu Pandurangi,
  • Kayla Hartjes,
  • Christopher Chu,
  • Alvaro Flores

摘要

Purpose of the Review

Our paper will outline a concise and comprehensive review of a practical approach to clinical metabolic dysfunction-associated steatotic liver disease (MASLD), incorporating considerations for risk factors, screening, diagnosis, and management, tailored for the pediatric demographic, with emphasis on risk factors and obesity medications.

Recent Findings

With the shift in terminology from non-alcoholic fatty liver disease (NAFLD) to MASLD, there is a clear need for pediatric guidelines that provide a practical approach to MASLD (Hampl et al. Pediatrics 151(1):e2022060640 [1]; Rinella et al. Hepatology 78(6):1966-1986 [2]; O'Hara et al. Obes Pillars 27(6):100066 [3]; Abou Jaoudeh et al. J Pediatr Gastroenterol Nutr 80(1):14-24 [4]). The combined MASLD guidelines from the European Association for the Study of Liver, Diabetes, and Obesity (EASL-EASD-EASO), published in July 2024 (EASL et al. J Hepatol 81(3):492-542 [5]), focused solely on the adult population. The most recent American Association for the Study of Liver Diseases AASLD publication in April 2025 offers an extensive evidence-based pediatric-focused practice statement on the evaluation and management of MASLD in children (Xanthakos et al. Hepatology [6]).

Summary

We hereby provide a concise and comprehensive review of a practical approach to clinical pediatric MASLD, with focus on risk factors, screening, management, and monitoring that could serve as a guide to primary care providers, gastroenterologists, hepatologists and other advanced health practitioners.